Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Leukemia. 2015 May 19;29(11):2162–2172. doi: 10.1038/leu.2015.127

Figure 6. Biologic effect of JUNB/STAT3 pharmacologic inhibition on ALK+ ALCL in Karpas 299 and SR-786.

Figure 6

A, and B. ALK+ ALCL cell lines Karpas 299 (A) and SR-786 (B) were treated with Stattic (10 µM), U0126 (10 µM), or both pharmacologic inhibitors. The proliferation of viable cells (MTT assay) was then measured 48 hours after treatment. Stattic and U0126 treatment in ALK+ ALCL resulted in dose-dependent cell proliferation arrest. Moreover, the combined treatment had an additive effect on the proliferation of both cell lines. C and D. Cell viability assessed by the trypan blue exclusion assay in Karpas 299 (C) and SR-786 cells (D) following combined treatment with Stattic and U0126 shows increased cell death compared to each drug alone. E. Colony formation of Karpas 299 cells was obliterated after treatment with both Stattic and U0126. F. Treatment with Stattic resulted in decreased number of colonies formed, while U0126 completely diminished visible colonies in SR-786. When both drugs were added in the medium (10 µM each) the results were similar with U0126 treatment alone (no colonies were visible).

p<0,05, **, p<0,01, ***, p<0,001 (Student’s t-test).